°æ±¸ Ç×»ýÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ¿ëµµº°, ¾àÁ¦ ¿ø·áº°, Ç×±Õ ½ºÆåÆ®·³º°, ¾àÁ¦ À¯Çüº°, Áö¿ªº°(2025-2033³â)
Oral Antibiotics Market Report by Class, Application (Community-acquired Respiratory Tract Infections, Urinary Tract Infections, Dental and Others), Drug Origin, Spectrum of Activity, Drug Type, and Region 2025-2033
»óǰÄÚµå : 1675321
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 147 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,221,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,628,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,036,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ °æ±¸ Ç×»ýÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 210¾ï 7,800¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 279¾ï 4,930¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³â¿¡ 3.18%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. °¨¿°ÁõÀÇ ¸¸¿¬, °í·ÉÀÚ Àα¸ÀÇ Áõ°¡, ¾àÁ¦ ³»¼º±Õ¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿Í À¯ÀüüÇÐÀÇ µ¿Çâ Áõ°¡ µîÀÌ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.

°æ±¸ Ç×»ýÁ¦´Â ÁÖ·Î ¼¼±ÕÀÇ Áõ½ÄÀ» ¾ïÁ¦Çϰųª ü³»¿¡¼­ ¼¼±ÕÀ» Á¦°ÅÇϱâ À§ÇØ Ã³¹æµÇ´Â ÀǾàǰÀÔ´Ï´Ù. º¸Åë ÀÔÀ¸·Î º¹¿ëÇϸç, ±¤¹üÀ§ÇÑ ÀÇ·á ÀûÀÀÁõ¿¡ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. °æ±¸ Ç×»ýÁ¦·Î Ä¡·áÇÒ ¼ö ÀÖ´Â °¨¿°ÁõÀÇ À¯ÇüÀº ÇǺÎ, ±Í, ¸ñ, ÀÎÈÄ, ¿ä·Î °¨¿°°ú °°Àº ÀϹÝÀûÀÎ ÁúȯºÎÅÍ Æó·Å°ú °°Àº º¹ÀâÇÑ Áúȯ±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ç×»ýÁ¦´Â ¿©·¯ À¯Çü·Î ºÐ·ùµÇ¸ç, °¢±â ´Ù¸¥ ÀÛ¿ë±âÀüÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÈçÈ÷ ó¹æµÇ´Â Ŭ·¡½º¿¡´Â Æä´Ï½Ç¸°°è, Ç÷ç¿À·ÎÄû³î·Ð°è, Åׯ®¶ó»çÀÌŬ¸°°è, ¸¶Å©·Î¸®µå°è µîÀÌ ÀÖ½À´Ï´Ù. °¢ °è¿­Àº ¼­·Î ´Ù¸¥ À¯ÇüÀÇ ¹ÚÅ׸®¾Æ¸¦ Ç¥ÀûÀ¸·Î »ï°í, ƯÁ¤ ¼¼±Õ °¨¿°¿¡ ´õ È¿°úÀûÀÔ´Ï´Ù. ¿¹¸¦ µé¾î Æä´Ï½Ç¸°°è´Â ¿¬¼â»ó±¸±Õ °¨¿°¿¡ ³Î¸® »ç¿ëµÇ¸ç, Ç÷ç¿À·ÎÄû³î·Ð°è´Â ƯÁ¤ ±×¶÷À½¼º±Õ¿¡ ´ëÇ×Çϱâ À§ÇØ ¼±Åõ˴ϴÙ. ±× °á°ú, °æ±¸ Ç×»ýÁ¦´Â Çö´ë ÇコÄɾîÀÇ Áß¿äÇÑ ¿ä¼ÒÀ̸ç, ¸¹Àº ¼¼±Õ °¨¿°ÀÇ ¼º°øÀûÀÎ Ä¡·á¸¦ À§ÇØ ÀÇ·á Àü¹®°¡µéÀÌ ³Î¸® ó¹æÇϰí ÀÖ½À´Ï´Ù.

°æ±¸ Ç×»ýÁ¦ ½ÃÀå µ¿Çâ :

°¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÀÌ·¯ÇÑ Áúº´¿¡ ´ëÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» Áö¿øÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ °¨¿°¼º Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×»ýÁ¦ÀÇ º¸±ÞÀ» ÃËÁøÇϰí Ç×»ýÁ¦ ³»¼ºÀÇ ÃâÇöÀ» ´ÊÃß°í ÀÌ·¯ÇÑ ¾à¹°ÀÇ È¿°ú¸¦ ´õ ¿À·¡ Áö¼Ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â Ç×»ýÁ¦ °ü¸® ÇÁ·Î±×·¥ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ç×»ýÁ¦ ³»¼º ¹®Á¦°¡ ½É°¢ÇØÁü¿¡ µû¶ó ¿¬±¸ÀÚµé°ú Á¦¾à»çµéÀº ±âÁ¸ Ç×»ýÁ¦ °è¿­À» º¯°æÇÏ°í ´ÙÁ¦³»¼º±Õ¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â »õ·Î¿î Ç×»ýÁ¦¸¦ °³¹ßÇÒ ¼ö¹Û¿¡ ¾ø¾î Á¦Ç° äÅà ¼Óµµ°¡ »¡¶óÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä Á¦¾à»ç ¹× ¿¬±¸±â°üµéÀº ¹ÚÅ׸®¾ÆÀÇ ³»¼º ÆÐÅÏÀ» ¿¹ÃøÇϰí, ¾à¹°°ú ¹ÚÅ׸®¾ÆÀÇ »óÈ£ÀÛ¿ëÀ» ÀÌÇØÇϸç, ½Å±Ô Ç×»ýÁ¦ ¹ß°ßÀ» °¡¼ÓÈ­Çϱâ À§ÇØ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)À» ½Å¾à°³¹ß °úÁ¤¿¡ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ È¯ÀÚÀÇ À¯ÀüÀû üÁú µîÀÇ ¿äÀÎÀ» °í·ÁÇÏ¿© ȯÀÚ °³°³Àο¡ ¸Â´Â Ç×»ýÁ¦ Ä¡·á¸¦ ÇÏ´Â ¸ÂÃãÀÇ·á¿Í À¯ÀüüÇÐÀÇ ºÎ»óÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â ¾àÁ¦ ³»¼º±Õ¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇコÄɾî ÀÎÇÁ¶ó °³¼±, »õ·Î¿î °æ±¸ Ç×»ýÁ¦ÀÇ Áö¼ÓÀûÀÎ Ãâ½Ã, ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ µîÀÌ ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ °æ±¸ Ç×»ýÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : Ŭ·¡½ºº°

Á¦7Àå ½ÃÀå ³»¿ª : ÀûÀÀº°

Á¦8Àå ½ÃÀå ³»¿ª : ¾àÁ¦ ¿ø·áº°

Á¦9Àå ½ÃÀå ³»¿ª : Ç×±Õ ½ºÆåÆ®·³º°

Á¦10Àå ½ÃÀå ³»¿ª : ¾àÁ¦ À¯Çüº°

Á¦11Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦12Àå ÃËÁø¿äÀΡ¤¾ïÁ¦¿äÀΡ¤±âȸ

Á¦13Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

Á¦15Àå °¡°Ý ºÐ¼®

Á¦16Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global oral antibiotics market size reached USD 21,078.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 27,949.3 Million by 2033, exhibiting a growth rate (CAGR) of 3.18% during 2025-2033. The increasing prevalence of infectious diseases, expanding geriatric population, escalating demand for effective treatments against drug-resistant bacteria, and the growing trend of personalized medicine and genomics represent some of the key factors driving the market.

Oral antibiotics are pharmaceutical agents primarily prescribed to inhibit bacterial growth or eliminate bacteria from the body. They are usually taken by mouth and are utilized across a wide range of medical applications. The types of infections treated by oral antibiotics vary and include common ailments such as skin, ear, throat, and urinary tract infections and more complex conditions like certain types of pneumonia. These antibiotics are categorized into different classes, each with a distinct mechanism of action. Some commonly prescribed classes include penicillins, fluoroquinolones, tetracyclines, and macrolides. Each class targets different types of bacteria and is more effective for specific bacterial infections. For instance, penicillins are widely used for streptococcal infections, while fluoroquinolones may be chosen to combat certain gram-negative bacteria. As a result, oral antibiotics are a key element of modern healthcare and are widely prescribed by healthcare professionals to enable the successful treatment of numerous bacterial infections.

Oral Antibiotics Market Trends:

The increasing prevalence of infectious diseases and the rising public awareness about the available treatment options for these conditions represent the primary factors supporting market growth. Moreover, the expanding geriatric population that is more susceptible to developing such infections is another major factor fueling the market growth. In addition, there has been a rise in antibiotic stewardship programs aimed at encouraging the widespread use of antibiotics, slowing down the emergence of antibiotic resistance, and ensuring the prolonged effectiveness of these drugs. Along with this, the growing issue of antibiotic resistance has compelled researchers and pharmaceutical companies to modify existing classes and develop new antibiotics capable of treating multi-drug resistant bacteria, thereby accelerating the product adoption rate. Furthermore, the leading pharmaceutical companies and research institutes are leveraging artificial intelligence (AI) and machine learning (ML) in the drug discovery process to predict bacterial resistance patterns, understand drug-bacteria interactions, and expedite the discovery of novel antibiotics. In line with this, the emergence of personalized medicine and genomics, which involves tailoring antibiotic treatment to individual patients by considering factors such as their genetic makeup to enhance treatment effectiveness and minimize side effects, has catalyzed market growth. Other factors, including escalating demand for effective treatments against drug-resistant bacteria, improving healthcare infrastructure, the continual launch of novel oral antibiotics, and heavy investments in research and development (R&D) activities, are also anticipated to propel the market growth in the coming years.

Key Market Segmentation:

Class Insights:

Application Insights:

Drug Origin Insights:

Spectrum of Activity Insights:

Drug Type Insights:

Regional Insights:

Competitive Landscape:

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Oral Antibiotics Market

6 Market Breakup by Class

7 Market Breakup by Application

8 Market Breakup by Drug Origin

9 Market Breakup by Spectrum of Activity

10 Market Breakup by Drug Type

11 Market Breakup by Region

12 Drivers, Restraints, and Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

15 Price Analysis

16 Competitive Landscape

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â